Indrayani Biotech (BSE: 526445) is a growth stock that is likely to show strong double digit growth over the next few years. In its Annual Report released the last week, the company has projected a consolidated revenue of Rs 150 crore for FY23. In comparison, the revenue for FY22 was Rs…
Read More
2022 is witnessing a sharp drop in global biotech investments by venture capital funds. Data compiled by Wisdomsmith shows venture capital funds invested $15.8B in biotech and healthcare sector over Jan-Apr’22, as compared to $27B over the same period in 2021. That’s a drop of 41%. While the drop…
Read More We recorded 79 VC/PE transactions pertaining to the global life sciences sector for September 2021, aggregating to a sum of USD 3.3B, as against 96 transactions and USD5.6B in Sep’20. The USA recorded 49 transactions aggregating to a total investment of USD 2.2B. China reported a totally out of character…
Read More We recorded 114 VC/PE transactions pertaining to the global life sciences sector for June 2021, aggregating to a sum of USD 6.47B. The USA recorded 69 transactions aggregating to a total investment of USD 3.26B. China reported investment of USD 886m from 11 VC/PE transactions. Rest of the world accounted…
Read More We recorded 94 VC/PE transactions pertaining to the global life sciences sector for May 2021, aggregating to a sum of USD 6.56B. The USA recorded 60 transactions aggregating to a total investment of USD 3.3B. China reported investment of USD 1.8B from 12 VC/PE transactions. Rest of the world accounted…
Read More We recorded 131 VC/PE transactions pertaining to the global life sciences sector for April 2021, aggregating to a sum of USD 6.5B. The USA recorded 88 transactions with total investment of USD 3.8B. China reported investment of USD 585m from 12 VC/PE transactions. Rest of world accounted for 31 transactions…
Read More We recorded 130 VC/PE transactions pertaining to the global life sciences sector for March 2021, aggregating to a sum of USD 9.2B. This is an all-time high deal count as well as amount. The USA recorded 86 transactions with total investment of USD 6.3B. China reported investment of USD 1.7B…
Read More
BeiGene’s outlicensing deal with Novartis underscores how Chinese pharma companies are yards ahead of Indian pharma companies now. Novartis, the Swiss Big Pharma company, has agreed to pay BeiGene $650 million upfront and up to $1.55 billion in potential regulatory and sales milestone payments plus royalties on product sales. This is in exchange…
Read More Founded in 2019, EQRx has closed 2 massive rounds in under 13 months. It first raised a Series-A round of USD200m in Jan’20 as part of its launch. Then in Jan’21, it has again shaken up the pharma world with a USD500m Series-B EQRx is targeting Equivalar medicines EQRx’ stated…
Read More We recorded 114 venture capital / private equity (VC/PE) transactions pertaining to the global life sciences sector for January 2021, aggregating to a sum of USD 6.275B. USA recorded 64 transactions for with total investment of USD 4B. China reported investment of USD 1B over 15 VC/PE transactions. India saw…
Read More